Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (40)
NITAG documentation (1618)
Reports (60)
SAGE documentation (226)
Scientific publications (120)
Systematic reviews (SYSVAC) (2973)
Regions
Africa (292)
Americas (777)
Eastern Mediterranean (56)
Europe (728)
Global (1)
South-East Asia (82)
Western Pacific (210)
Diseases
Chikungunya (11)
Cholera (35)
COVID-19 (1552)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (83)
Ebola (17)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (69)
Hepatitis A (65)
Hepatitis B (163)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (515)
Influenza (610)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (31)
Measles (139)
Meningococcal disease (151)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (47)
Pertussis (113)
Pneumococcal disease (292)
Poliomyelitis (89)
Q fever (1)
Rabies (31)
Rotavirus (118)
RSV (Respiratory syncytial virus) (58)
Rubella (66)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (64)
Tick-borne encephalitis (12)
Tuberculosis (79)
Typhoid (27)
Varicella (75)
Yellow fever (44)
Zika (1)
Show more
5037 results found
2024
∙
NIAC
NIAC updated recommendations for COVID-19 primary schedule vaccination
2024
∙
ACIP
Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023
2024
∙
ACIP
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season
2024
∙
ACIP
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the ACIP — United States, 2024
2024
∙
ACIP
ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
2024
∙
ACIP
ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
2024
∙
ACIP
GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults
2024
∙
ACIP
GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults
2024
∙
NACI
NACI Interpretation Guide – Health Economics
2024
∙
Eliza Dryer, Abigail Shefer, Shalini Desai, Lance Rodewald, Magdalena Bastias, Nathalie El Omeiri, Sidy Ndiaye, Kori Cook, Louise Henaff, Erin Kennedy
Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups (NITAGs)
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register